Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Universal DNA screening in endometrial cancer reveals hidden genetic risks

NCT ID NCT03460483

Knowledge-focused Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested over 1,000 women with endometrial cancer for DNA repair problems that can be inherited (Lynch syndrome). By analyzing tumor DNA, researchers aimed to personalize cancer treatment and identify family members who might also be at risk. The goal was to improve care and outcomes for patients and their relatives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,001 people

The number who actually took part.

Started

Mar 2018

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult women who had a hysterectomy or diagnostic biopsy proving endometrial adenocarcinoma (any stage) between 10/1/2017 and 4/30/2020, and received care at one of the participating hospitals * Adult relatives of the EC patients found to have LS Exclusion Criteria: * Individuals must be able to speak and read English; non-English speaking individuals will be excluded * Individuals must be able to consent for themselves; those who are unable to consent for themselves for any reason will be excluded * Prisoners will be specifically excluded from participation in the study * Women who have uterine sarcomas are excluded * Pregnant women are not eligible for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Colorectal Neoplasms, Hereditary Nonpolyposis endometrial carcinoma endometrium adenocarcinoma endometrium neoplasm Lynch syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial adenocarcinoma Endometrial carcinoma Lynch syndrome Relatives

Contacts and locations

Locations

  • Aultman Health Foundation

    Canton, Ohio, 44710, United States

  • Mercy Health - St. Vincent Medical Center

    Toledo, Ohio, 43608, United States

  • MetroHealth Medical Center

    Cleveland, Ohio, 44109, United States

  • Ohio Health

    Columbus, Ohio, 43214, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Summa Akron City Hospital/Cooper Cancer Center

    Akron, Ohio, 44304, United States

  • TriHealth Cancer Institute-Westside

    Cincinnati, Ohio, 45245, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.